EA201591807A1 - Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках - Google Patents

Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках

Info

Publication number
EA201591807A1
EA201591807A1 EA201591807A EA201591807A EA201591807A1 EA 201591807 A1 EA201591807 A1 EA 201591807A1 EA 201591807 A EA201591807 A EA 201591807A EA 201591807 A EA201591807 A EA 201591807A EA 201591807 A1 EA201591807 A1 EA 201591807A1
Authority
EA
Eurasian Patent Office
Prior art keywords
content
sialic acid
lysin
galactose
methods
Prior art date
Application number
EA201591807A
Other languages
English (en)
Inventor
Марсель Фликвеерт
Чарльз Гучи
Франсис Масланка
Францискус Йоханнес Игнатиус Нагель
Джеймс Райланд
Юджин Шефер
Original Assignee
Янссен Байотек, Инк.
Янссен Байолоджикс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Байотек, Инк., Янссен Байолоджикс Б.В. filed Critical Янссен Байотек, Инк.
Publication of EA201591807A1 publication Critical patent/EA201591807A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

В настоящем патенте раскрывается способ создания антитела, например анти-ФНО-α-антитела (т.е. инфликсимаб), имеющего содержание С-концевого лизина от 20 до 70%, содержание сиаловой кислоты от 1 до 20%, содержащего цинкреагирующие клетки-хозяева, трансфицированные ДНК, кодирующей антитело в культурной среде, содержащей по меньшей мере 0,5 мкмоль/л цинка, и контроль концентрации цинка в культурной среде для создания антитела.
EA201591807A 2013-03-15 2014-03-07 Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках EA201591807A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15
PCT/US2014/021574 WO2014149935A1 (en) 2013-03-15 2014-03-07 Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Publications (1)

Publication Number Publication Date
EA201591807A1 true EA201591807A1 (ru) 2016-02-29

Family

ID=51528780

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591807A EA201591807A1 (ru) 2013-03-15 2014-03-07 Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках

Country Status (26)

Country Link
US (3) US20140273092A1 (ru)
EP (1) EP2970980B2 (ru)
JP (1) JP2016512029A (ru)
KR (1) KR102216003B1 (ru)
CN (1) CN105378086B (ru)
AR (2) AR095660A1 (ru)
AU (2) AU2014237635B2 (ru)
BR (1) BR112015022971B1 (ru)
CA (1) CA2907140A1 (ru)
CY (1) CY1120980T1 (ru)
DK (1) DK2970980T3 (ru)
EA (1) EA201591807A1 (ru)
ES (1) ES2690047T3 (ru)
HR (1) HRP20181741T1 (ru)
IL (1) IL240689B (ru)
LT (1) LT2970980T (ru)
MX (1) MX366910B (ru)
PH (1) PH12015501837A1 (ru)
PL (1) PL2970980T3 (ru)
PT (1) PT2970980T (ru)
RS (1) RS57791B1 (ru)
SG (1) SG11201507577RA (ru)
SI (1) SI2970980T1 (ru)
TW (1) TWI630216B (ru)
WO (1) WO2014149935A1 (ru)
ZA (1) ZA201507671B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX366910B (es) * 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
BR112016002622B1 (pt) 2013-08-20 2023-04-11 Lek Pharmaceuticals D.D Meio de cultura celular e uso de selênio
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CN108350416A (zh) * 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
WO2017106684A2 (en) 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
JP7178342B2 (ja) 2016-08-12 2022-11-25 ヤンセン バイオテツク，インコーポレーテツド アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
JP2020522266A (ja) 2017-06-05 2020-07-30 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２−ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
CA3065516A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
MX2020012589A (es) 2018-05-24 2021-01-29 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
MX2021008030A (es) * 2018-12-31 2021-08-05 Momenta Pharmaceuticals Inc Metodos para producir ustekinumab.
EP4004057A1 (en) 2019-07-26 2022-06-01 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CA3148121A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
IL302349A (en) 2020-03-13 2023-06-01 Janssen Biotech Inc Materials and methods for binding SIGLEC-3/CD33
CR20220594A (es) 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
US11827708B2 (en) 2020-07-29 2023-11-28 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses
EP4228693A1 (en) 2020-10-13 2023-08-23 Janssen Biotech, Inc. Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
KR20230110523A (ko) 2020-10-22 2023-07-24 얀센 바이오테크 인코포레이티드 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
BR112023015097A2 (pt) 2021-01-28 2023-10-03 Janssen Biotech Inc Proteínas de ligação a psma e usos das mesmas
IL306103A (en) 2021-03-24 2023-11-01 Janssen Biotech Inc The antibody targets CD22 and CD79B
IL306132A (en) 2021-03-24 2023-11-01 Janssen Biotech Inc Proteins containing CD3 antigen binding sites and uses thereof
WO2023037333A1 (en) 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023089587A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0610201B2 (en) * 1991-03-18 2007-09-26 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (ru) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
JP4833991B2 (ja) 2004-11-02 2011-12-07 アレス トレーディング ソシエテ アノニム 哺乳動物細胞のための無血清細胞培養培地
WO2009126564A1 (en) * 2008-04-07 2009-10-15 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
RU2580020C2 (ru) * 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
MX366910B (es) * 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.

Also Published As

Publication number Publication date
SI2970980T1 (sl) 2018-11-30
BR112015022971B1 (pt) 2022-05-17
KR20150129025A (ko) 2015-11-18
AU2014237635B2 (en) 2020-03-12
MX366910B (es) 2019-07-30
EP2970980B2 (en) 2022-07-27
AU2014237635A1 (en) 2015-09-03
JP2016512029A (ja) 2016-04-25
EP2970980A1 (en) 2016-01-20
ZA201507671B (en) 2017-11-29
WO2014149935A1 (en) 2014-09-25
AR124871A2 (es) 2023-05-17
AR095660A1 (es) 2015-11-04
CY1120980T1 (el) 2019-12-11
BR112015022971A2 (pt) 2017-11-14
PL2970980T3 (pl) 2019-01-31
PH12015501837B1 (en) 2015-11-09
AU2020203864B2 (en) 2022-05-26
MX2015012361A (es) 2016-04-28
TWI630216B (zh) 2018-07-21
US20160237149A1 (en) 2016-08-18
AU2020203864A1 (en) 2020-07-02
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
EP2970980B1 (en) 2018-08-15
DK2970980T3 (en) 2018-10-22
IL240689B (en) 2021-12-01
EP2970980A4 (en) 2016-09-07
US20140273092A1 (en) 2014-09-18
IL240689A0 (en) 2015-10-29
PH12015501837A1 (en) 2015-11-09
KR102216003B1 (ko) 2021-02-16
RS57791B1 (sr) 2018-12-31
CN105378086A (zh) 2016-03-02
TW201441263A (zh) 2014-11-01
PT2970980T (pt) 2018-11-19
CA2907140A1 (en) 2014-09-25
LT2970980T (lt) 2018-10-25
HRP20181741T1 (hr) 2018-12-28
CN105378086B (zh) 2019-05-28
ES2690047T3 (es) 2018-11-19
US20220089712A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
EA201591807A1 (ru) Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
MY183415A (en) Anti-c5 antibodies and methods of use
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX337184B (es) Proceso para purificar proteinas.
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
WO2016048995A3 (en) Fgf19 truncations and mutants and uses thereof
AR095418A1 (es) Métodos para aumentar el contenido de manosa en proteínas recombinantes
EA201270015A1 (ru) Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
RU2020115514A (ru) Контролирование образования дисульфидных связей в белковых растворах с помощью добавления восстанавливающих средств
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
EP2496608A4 (en) FUSION PROTEIN SPECIFICALLY BINDING TO A CONSTANT REGION OF ANTIBODY, PREPARATION THEREFOR, AND METHOD OF ISOLATING ANTIBODY USING THE SAME
AU2018276376A1 (en) Cell culture methods
EA201591558A1 (ru) Составы и способы увеличения производства рекомбинантного белка
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
MX2017008633A (es) Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
MX2013013063A (es) Plantas que tienen rasgos mejorados relacionados con el rendimiento y metodo para elaborar las mismas.
WO2012140588A8 (en) Production of heterologous extracellular polypeptides in yarrowia lipolytica
AR111291A1 (es) Método para purificar un anticuerpo
WO2018208121A3 (ko) Mrs에 특이적으로 결합하는 모노클로날 항체